Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas

AKYERLİ BOYLU C., Yuksel S., CAN Ö., Erson-Omay E. Z., OKTAY Y., Cosgun E., ...More

JOURNAL OF NEUROSURGERY, vol.128, no.4, pp.1102-1114, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 128 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.3171/2016.11.jns16973
  • Journal Name: JOURNAL OF NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1102-1114
  • Keywords: glioma, isocitrate dehydrogenase, telomerase, mutation, prognosis, oncology
  • Dokuz Eylül University Affiliated: Yes

Abstract

OBJECTIVE Recent studies have established that hemispheric diffuse gliomas may be grouped into subsets on the basis of molecular markers; these subsets are loosely correlated with the histopathological diagnosis but are strong predictors of clinical tumor behavior. Based on an analysis of molecular and clinical parameters, the authors hypothesized that mutations of the telomerase promoter (TERTp-mut) mark separate oncogenic programs among isocitrate dehydrogenase 1 and/or 2 (IDH) mutant (IDH-mut) and IDH wild-type (IDH-wt) diffuse gliomas independent of histopathology or WHO grade.